A phase II multi-center study to evaluate the efficacy and safety of 500mg fulvestrant (Faslodex) as a first-line hormonal treatment in postmenopausal women with hormone receptor-positive metastatic breast cancer
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2007
At a glance
- Drugs Fulvestrant (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 20 Apr 2007 New trial record.